| Date Filed | Type | Description |
| 08/16/2023 |
4
| Anderson Glen R. (10% Owner) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Bought 44,354 shares
@ $1.94, valued at
$86k
Bought 35,064 shares
@ $2.12, valued at
$74.3k
Bought 23,934 shares
@ $2.34, valued at
$56k
|
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
8-K
| Other Events Interactive Data |
| 08/07/2023 |
4
| Waltzman Roger J. (Chief Medical Officer) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 90,000 options to buy
@ $1.85, valued at
$166.5k
|
|
| 08/07/2023 |
3
| Waltzman Roger J. (Chief Medical Officer) has filed a Form 3 on Indaptus Therapeutics, Inc. |
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/24/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/17/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
4
| Martell Robert (Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 20,000 options to buy
@ $1.71, valued at
$34.2k
|
|
| 02/14/2023 |
3
| Martell Robert (Director) has filed a Form 3 on Indaptus Therapeutics, Inc. |
| 02/14/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/20/2023 |
4
| Meckler Jeffrey A (CEO and Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $1.61, valued at
$161k
|
|
| 01/20/2023 |
4
| Linscott Walt Addison (Chief Business Officer) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.61, valued at
$64.4k
|
|
| 01/20/2023 |
4
| Sassi Nir (CFO) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.61, valued at
$64.4k
|
|
| 01/20/2023 |
4
| Newman Michael James (CSO and Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 43,250 options to buy
@ $1.61, valued at
$69.6k
|
|
| 01/03/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/30/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/22/2022 |
4
| Meckler Jeffrey A (CEO and Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Bought 400 shares
@ $1.7637, valued at
$705.5
Bought 9,600 shares
@ $1.9, valued at
$18.2k
|
|
| 10/03/2022 |
4
| Karah Hila (Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 13,750 options to buy
@ $2.16, valued at
$29.7k
|
|
| 10/03/2022 |
4
| Pomerantz Roger (Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 81,000 options to buy
@ $2.16, valued at
$175k
|
|
| 10/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/03/2022 |
4
| O'CALLAGHAN BRIAN (Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 13,750 options to buy
@ $2.16, valued at
$29.7k
|
|
| 10/03/2022 |
4
| MADDALUNA ANTHONY J (Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 13,750 options to buy
@ $2.16, valued at
$29.7k
|
|
| 10/03/2022 |
4
| Hayes William B (Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Granted 13,750 options to buy
@ $2.16, valued at
$29.7k
|
|
| 09/30/2022 |
8-K
| Quarterly results |
| 09/12/2022 |
4
| Meckler Jeffrey A (CEO and Director) has filed a Form 4 on Indaptus Therapeutics, Inc.|
Txns:
| Bought 10,308 shares
@ $2.8, valued at
$28.9k
|
|
| 09/12/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|